Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study-Reference-Cited by-同舟云学术

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

Published:2017-05 Issue:5 Volume:18 Page:640-653
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Thuss-Patience Peter C,Shah Manish A,Ohtsu Atsushi,Van Cutsem Eric,Ajani Jaffer A,Castro Hugo,Mansoor Wasat,Chung Hyun Cheol,Bodoky Gyorgy,Shitara Kohei,Phillips Gail D Lewis,van der Horst Tina,Harle-Yge Marie-Laurence,Althaus Betsy L,Kang Yoon-Koo

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer;Van Cutsem;Gastric Cancer,2015

2. HER2 testing in gastric cancer: a practical approach;Rüschoff;Mod Pathol,2012

3. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab;Gomez-Martin;J Clin Oncol,2013

4. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010

5. Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data;Janowitz;Br J Cancer,2016

Cited by 419 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation;npj Precision Oncology;2024-09-09

2. HER2-low gastric cancer: is the subgroup targetable?;ESMO Open;2024-09

3. Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?;Cancer Treatment Reviews;2024-09

4. HER-2 directed therapies across gastrointestinal tract cancers – A new frontier;Cancer Treatment Reviews;2024-09

5. The Impact of Pembrolizumab as a Salvage Therapy Based on HER2 Expression in Advanced Gastric Cancer;Cancers;2024-08-26